Hanmi Pidogul receives EU MA for first IMD

Export foreseen in the first half year to 8 countries including UK, Germany and Netherlands

Pidogul, Hanmi pharmaceutical's anti-thrombotic drug has received marketing authorization from 8 European countries for first Korean incrementally modified drug (IMD).

Hanmi, on 16th announced that it had been granted the marketing authorization (MA) from Italy last December, and has recently received the certificate of registration.

Therefore MA granted European countries are now expanded up to 8 countries including UK, Germany, Portugal, Spain, Netherlands, Cyprus and Italy.

Among Korean pharmaceutical companies Hanmi Pidogul is the first IMD which has received marketing authorization in European area.

Hanmi has completed European clinical studies and starting from the year of 2009 it went through marketing authorization procedure in each of the countries. On November 25, 2010 Hanmi has received the first marketing authorization from UK Medicines and healthcare products regulatory agency (MHRA) and from Italy on December 14, 2011 and thus is able to market Pidogul all over Europe.

Hanmi with AET, German company, are currently seeking for partners to market the product in each of the countries and expects to export Pidogul in the first half of the year.

Hanmi's personnel commented "Hanmi had already been exporting the API of Pidogul, Clopidogrel to Europe starting from 2008.Europe."